Results 101 to 110 of about 11,904 (210)

Rivastigmine Adverse Effects: Complete Heart Block

, 2010
Context: Rivastigmine (Exelon), a brain selective cholinesterase inhibitor, is used in the treatment of Alzheimer’s Disease (AD) to improve cognitive functions.Case Report: We report a case in which the addition of rivastigmine to memantine and ...
Mastrine, DO, Lou, Hollander, MD, Gerald, Esses, MD, Jason, Amley, MD, Xixi   +3 more
core  

Formulation of Rivastigmine Niosomes for Alzheimer Disease

, 2018
Introduction: Alzheimer is a brain dysfunctional disease which could destroy the cognition and learning capabilities of the patient. Rivastigmine is an acetylcholine esterase inhibitor which can improve brain function in both Alzheimer and Parkinson's ...
Hamidifar, Zohreh, Raeisi Estabragh, Mohammad Amin, Pardakhty, Abbas   +2 more
core   +1 more source

A prospective study on the use of rivastigmine transdermal patch in Alzheimer's dementia in a routine clinical setting

Dementia & Neuropsychologia
There is not much published literature on the use of rivastigmine patch in a "routine" clinical setting. Objectives: In this naturalistic longitudinal observational study we sought to evaluate the safety, tolerability and efficacy of the rivastigmine ...
Ejaz Nazir, Muhammad Mushtaq
doaj   +1 more source

Which Rivastigmine Formula is Better for Heart in Elderly Patients With Alzheimer's Disease: Oral or Patch?

, 2014
Objective: Rivastigmine is commonly used for the treatment of Alzheimer's disease (AD). All cholinesterase inhibitors, including rivastigmine, may cause cardiac side effects.
Yay, Adnan, IŞIK, AHMET TURAN, Soysal, Pinar   +2 more
core   +1 more source

Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2)

, 2010
Transportations of rivastigmine containing liposomes across Caco-2 cells were studied and in vitro test results were compared with in vivo results. MTT test was used for cell viability studies. Series of formulations were prepared containing rivastigmine
Mutlu, N. B., Degim, Z., Nacar, AHMET, ESSIZ, D., Nacar, A., Yilmaz, S., Mutlu, NECİBE BAŞARAN   +6 more
core   +1 more source

Pharmacokinetic rationale for the rivastigmine patch.

, 2007
The dual cholinesterase inhibitor rivastigmine is approved in capsule form in many countries for the symptomatic treatment of dementia associated with Alzheimer disease (AD) and Parkinson disease (PD).
Lefevre, Gilbert, Appel Dingemanse, Silke, Cummings, Jeffrey, Small, Gary   +3 more
core  

Identification of responders and reactive domains to rivastigmine in Alzheimer's disease

, 2007
PURPOSE: Presently, it is unclear which patients suffering from Alzheimer's Disease (AD) respond to rivastigmine and if rivastigmine acts on specific cognitive domains.
Koks, C H W, Beijnen, J H, Tulner, L.R., de Boer, A, Appels, B. A., Schmand, B A, Appels, B A, Appels, B.A., Dep Farmaceutische wetenschappen, Koks, C. H. W., van Campen, J P C M, Frankfort, S.V., Schmand, B.A., Koks, C.H., van Campen, J. P. C. M., Tulner, L. R., Frankfort, S V, de Boer, A. [=Anthonius], Beijnen, J. H., de Boer, A., Beijnen, J.H., Tulner, L R, Sub Pharmacotherapy, Theoretical, Frankfort, S. V., Sub Clinical Pharmacology, van Campen, J.P., Schmand, B. A.   +26 more
core   +1 more source

Rivastigmine for the treatment of Parkinson’s disease dementia

, 2010
Dementia is a common and important complication of Parkinson’s disease (PD), and adequate treatment is of great importance. Evidence from one large randomized controlled trial and three open-label studies suggest that rivastigmine can improve cognitive ...
Serge Gauthier, Uwe Ehrt, Dag Aarsland
core   +1 more source

Movement disorders associated with acetylcholinesterase inhibitors in Alzheimer’s dementia: A systematic review

Brain Circulation
BACKGROUND: Acetylcholinesterase inhibitors (AChEIs) are widely used in Alzheimer’s disease (AD). This study aims to systematically review the literature about movement disorders (MDs) associated with AChEIs for AD, which include donepezil, galantamine ...
Jamir Pitton Rissardo, Ana Letícia Fornari Caprara   +1 more
doaj   +1 more source

Cholinesterase inhibition by rivastigmine in colon, plasma, and brain of DSS drinking treated mice.

, 2013
Rivastigmine 0.5 or 1 = mice treated with rivastigmine (0.5 mg/kg or 1 mg/kg) once daily. Data represent percent ChE inhibition induced by rivastigmine compared to that in mice treated with PBS and drinking DSS.
Shai Shoham (383580), Mirela Nadler-Milbauer (383579), Helena Shifrin (383578), Marta Weinstock (383581)   +3 more
core   +1 more source